ANTIIDIOTYPIC MONOCLONAL-ANTIBODY AB3, REACTING WITH the PRIMARY ANTIGEN (CEA), CAN LOCALIZE in HUMAN COLON-CARCINOMA XENOGRAFTS AS EFFICIENTLY AS AB1
Demoraes, J. Z.
Gesztesi, J. L.
Ledoussal, J. M.
Lopes, J. D.
Mach, J. P.
Is part ofInternational Journal of Cancer
MetadataShow full item record
BALB/c mice were immunized with anti-idiotypic monoclonal (MAb) antibody (anti-Id or Ab2) directed against an AB1 MAb anti-carcinoembryonic (CEA) in order to obtain AB3 MAbs (anti-anti-Id). AB3 MAbs were shown to recognise the primary antigen (CEA) and one of them was tested extensively in vitro and in vivo. This AB3 MAb was shown to bind specifically to CEA on frozen sections of a human colon carcinoma by immuoperoxidase. Scatchard plot analyses showed that the affinity of this AB3 was of the same order of magnitude as the AB1. in vivo experiments, in nude mice bearing CEA-producing human colon-carcinoma xenografts showed that up to 30% of the intravenously injected dose of I-125-labelled AB3 were localized per gram of tumour tissue. Furthermore, calculation of the ratios of AB3 concentration in the tumour over those in normal organs such as lung, liver, kidney, spleen and bone gave relatively high values similar to results obtained with AB1. All together our results show that AB3 can localize as efficiently and specifically in the tumour as AB1, despite the fact that the mice from which it was derived were immunized with a mouse MAb (AB2) and had never been exposed to CEA. (C) 1994 Wiley-Liss, Inc.
CitationInternational Journal of Cancer. New York: Wiley-liss, v. 57, n. 4, p. 586-591, 1994.
- Em verificação - Geral